Market Cap 114.45M
Revenue (ttm) 3.55M
Net Income (ttm) -14.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -419.15%
Debt to Equity Ratio 0.00
Volume 89,000
Avg Vol 226,290
Day's Range N/A - N/A
Shares Out 20.92M
Stochastic %K 20%
Beta 0.20
Analysts Strong Sell
Price Target $16.00

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
VINCE_CARTER
VINCE_CARTER Dec. 26 at 9:44 PM
$COYA Intriguing chart. What is the bull case here? P2 is still early when I'm looking at potential cash burn? Any competition or is Coya first mover? What's the TAM? Thanks
2 · Reply
AgentMulder
AgentMulder Dec. 26 at 8:46 PM
$COYA Added after listening to Lou B’s interview w/CEO! ‘26 looks really splendid here….thx JW!
0 · Reply
Mad1line_Hampton
Mad1line_Hampton Dec. 26 at 7:12 PM
$COYA biotech microcap quiet accumulation watch ignition
0 · Reply
mwb1
mwb1 Dec. 26 at 6:29 PM
$COYA I've taken a meaningful position here over the last week, adding 10k shares. We know that neuroinflammation is a key player in the doom loop of neurodegenerative diseases. It seems that, depending on the particular case, inflammation can initiate damage, accelerate it, or lock it into place. But in all cases, reducing inflammation should help. The Nobel prize going to one of Coya's scientific advisors for the discovery of the role that Tregs play in inflammation adds a lot of weight to Coya's thesis. Strong cash position, already partnered, and solid early data. What am I missing? This looks like a great asymmetric investment to me.
1 · Reply
Jwa68
Jwa68 Dec. 26 at 2:01 PM
$COYA Conservative fair value is easily $9 as I write this. Deep value and highly favorable asymmetric risk. Added 35k shares recently and may add more sub $6 . Looking forward to Jan.
1 · Reply
OnlyFibs
OnlyFibs Dec. 26 at 4:44 AM
Follow the Insider Breadcrumbs to the ALSTARS Catalyst 🥖🧬 The $COYA tape is whispering what the 11 insiders already know. While the crowd fixed on the $5.50 offering, Dr. Reddy’s just cut a $4.2M check for the first Phase 2 patient dosing. With Health Canada greenlighting the expansion on Dec 23rd, the clinical engine is at full throttle. Bull Breakout: A daily close over $6.10 triggers the squeeze to the $18.00 analyst high. Bear Floor: Defending the $5.34 trendline shelf. If the $4.65 macro floor snaps, the thesis resets. Alpha: 0.03 put/call ratio means the bears have officially left the building. 🏢🚢 #hovdid
0 · Reply
RunnerSignals
RunnerSignals Dec. 25 at 5:39 PM
Analyst buzz is loud around $ANNX $COYA $CANG $PAAS $CRM. Big upside targets, Strong Buys and momentum building fast. which upgrade delivers first? https://stocksrunner.com/news/2025-12-25-stock-upgrades-highlight-top-picks
0 · Reply
Jwa68
Jwa68 Dec. 24 at 3:54 PM
$COYA Just added another 20k shares. Things can change in a split second. Current price is one of the single best asymmetric opportunities I've seen in a long time next to $GANX. Both companies are set to make a big impact on neurodegenerative diseases and both likely see new names on the door by mid 26 in my mind. DYDD
4 · Reply
foreverboner
foreverboner Dec. 24 at 3:30 PM
$COYA im jealous of the guy who got this share. killer trade
1 · Reply
Spidey69
Spidey69 Dec. 24 at 10:30 AM
$COYA please say this is inaccurate?
1 · Reply
Latest News on COYA
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 5:17 PM EST - 11 months ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD


Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 31, 2024, 10:31 AM EDT - 1 year ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off


Coya Therapeutics Announces $10.0 Million Private Placement

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Coya Therapeutics Announces $10.0 Million Private Placement


VINCE_CARTER
VINCE_CARTER Dec. 26 at 9:44 PM
$COYA Intriguing chart. What is the bull case here? P2 is still early when I'm looking at potential cash burn? Any competition or is Coya first mover? What's the TAM? Thanks
2 · Reply
AgentMulder
AgentMulder Dec. 26 at 8:46 PM
$COYA Added after listening to Lou B’s interview w/CEO! ‘26 looks really splendid here….thx JW!
0 · Reply
Mad1line_Hampton
Mad1line_Hampton Dec. 26 at 7:12 PM
$COYA biotech microcap quiet accumulation watch ignition
0 · Reply
mwb1
mwb1 Dec. 26 at 6:29 PM
$COYA I've taken a meaningful position here over the last week, adding 10k shares. We know that neuroinflammation is a key player in the doom loop of neurodegenerative diseases. It seems that, depending on the particular case, inflammation can initiate damage, accelerate it, or lock it into place. But in all cases, reducing inflammation should help. The Nobel prize going to one of Coya's scientific advisors for the discovery of the role that Tregs play in inflammation adds a lot of weight to Coya's thesis. Strong cash position, already partnered, and solid early data. What am I missing? This looks like a great asymmetric investment to me.
1 · Reply
Jwa68
Jwa68 Dec. 26 at 2:01 PM
$COYA Conservative fair value is easily $9 as I write this. Deep value and highly favorable asymmetric risk. Added 35k shares recently and may add more sub $6 . Looking forward to Jan.
1 · Reply
OnlyFibs
OnlyFibs Dec. 26 at 4:44 AM
Follow the Insider Breadcrumbs to the ALSTARS Catalyst 🥖🧬 The $COYA tape is whispering what the 11 insiders already know. While the crowd fixed on the $5.50 offering, Dr. Reddy’s just cut a $4.2M check for the first Phase 2 patient dosing. With Health Canada greenlighting the expansion on Dec 23rd, the clinical engine is at full throttle. Bull Breakout: A daily close over $6.10 triggers the squeeze to the $18.00 analyst high. Bear Floor: Defending the $5.34 trendline shelf. If the $4.65 macro floor snaps, the thesis resets. Alpha: 0.03 put/call ratio means the bears have officially left the building. 🏢🚢 #hovdid
0 · Reply
RunnerSignals
RunnerSignals Dec. 25 at 5:39 PM
Analyst buzz is loud around $ANNX $COYA $CANG $PAAS $CRM. Big upside targets, Strong Buys and momentum building fast. which upgrade delivers first? https://stocksrunner.com/news/2025-12-25-stock-upgrades-highlight-top-picks
0 · Reply
Jwa68
Jwa68 Dec. 24 at 3:54 PM
$COYA Just added another 20k shares. Things can change in a split second. Current price is one of the single best asymmetric opportunities I've seen in a long time next to $GANX. Both companies are set to make a big impact on neurodegenerative diseases and both likely see new names on the door by mid 26 in my mind. DYDD
4 · Reply
foreverboner
foreverboner Dec. 24 at 3:30 PM
$COYA im jealous of the guy who got this share. killer trade
1 · Reply
Spidey69
Spidey69 Dec. 24 at 10:30 AM
$COYA please say this is inaccurate?
1 · Reply
Jwa68
Jwa68 Dec. 23 at 9:31 PM
$COYA FTD data imminent. I'm optimistic...very. https://www.yahoo.com/entertainment/celebrity/articles/bruce-willis-wife-shares-heartbreaking-173505349.html
1 · Reply
Chrissytina
Chrissytina Dec. 23 at 5:33 PM
$COYA Everything is good with this company except the stock price 😡
1 · Reply
JohnTrack
JohnTrack Dec. 23 at 4:20 PM
$COYA keeping it warm, maybe later!
0 · Reply
prismmarketview
prismmarketview Dec. 23 at 3:35 PM
$COYA advances its Phase 2 ALS program with Health Canada CTA acceptance for COYA 302, enabling patient enrollment in Canada and expanding the ongoing ALSTARS trial alongside U.S. sites. https://prismmarketview.com/coya-therapeutics-advances-phase-2-als-program-with-health-canada-cta-acceptance/
0 · Reply
foreverboner
foreverboner Dec. 23 at 2:01 PM
$COYA ooh canada.
1 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 1:45 PM
D. Boral Capital has updated their rating for Coya Therapeutics ( $COYA ) to Buy with a price target of 15.
0 · Reply
TapeTrack_1721
TapeTrack_1721 Dec. 23 at 1:43 PM
$COYA microcap biotech, tight coil and low attention sets up asymmetry if volume ignites
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 1:34 PM
$COYA Receives Clinical Trial Application (CTA) Acceptance https://www.rapidticker.com/news/coya-coya-therapeutics-receives-clinical-trial-4bbbde
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 23 at 1:31 PM
$COYA Share Price: $5.36 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.54 – $0.66 Target Zone: $0.87 – $1.06 Potential Upside: 53% ROI Time to Expiration: 240 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 23 at 1:00 PM
$COYA Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
0 · Reply
Jwa68
Jwa68 Dec. 22 at 7:42 PM
$COYA Really great interview just out with Lou Basenese and Arun Swaminathan, Coya CEO. https://x.com/LouBasenese/status/2003188209799549283?s=20
2 · Reply
Jwa68
Jwa68 Dec. 22 at 6:21 PM
$COYA https://www.fiercepharma.com/pharma/als-med-radicava-change-hands-shionogi-inks-25b-buyout
1 · Reply